⌘K
Loading ticker…
As of 2026-08-24, BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) has a 3-month relative strength percentile of 61 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 47. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 1.29×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
BBOT is held by 3 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $2M notional. Top 3 carry $3M.
Held by 7 ETFs · $11M across latest filings · largest weight 0.48% (CANC).
Top 3 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| CANC | 0.48% | $837K | new |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $247K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
Not enough history to compute monthly seasonality for BBOT.